[CAS NO. 2630904-45-7] MRTX-1719
PRODUCTS SPECIFICATIONS [2630904-45-7]
DESCRIPTION [2630904-45-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 464.88 |
| Molecular Formula | C23H18ClFN6O2 |
| SMILES | FC1=C(Cl)C=C(OC2CC2)C(C#N)=[C@]1[C@]3=C(C=NN3C)C4=CC=C(C(NN=C5CN)=O)C5=C4 |
Summary
MRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC 50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells [1] .
IC50 & Target
|
PRMT5 |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05245500 | Mirati Therapeutics Inc. |
Mesothelioma|Non Small Cell Lung Cancer|Malignant Peripheral Nerve Sheath Tumors|Solid Tumor|Pancreatic Adenocarcinoma|Advanced Solid Tumor
|
June 2, 2022 | Phase 1|Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 215.11 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1511 mL | 10.7555 mL | 21.5109 mL |
| 5 mM | 0.4302 mL | 2.1511 mL | 4.3022 mL |
| 10 mM | 0.2151 mL | 1.0755 mL | 2.1511 mL |